The animal experiment was approved by the Institutional Animal Care and Use Committee of Emory University. Tu686 cells (1.5×106) were injected subcutaneously into 4–5 week-old female nude mice (athymic nu/nu, Taconic NY). When the tumors had developed to about 100mm3, the mice were divided into four groups (n=6 per group) and treated as follows:1) control treated with 20% intralipid (Baxter Healthcare), 2) honokiol (50mg/kg), 3) RT (1.5Gy every other day for 5 treatments), 4) honokiol (50mg/kg) plus RT (1.5Gy, every other day for 5 treatments). Honokiol was administered 3 times per week via intraperitoneal injection. For RT, mice were irradiated with 1.5Gy every other day for 5 treatments. The therapy was continued for 4 weeks. The body weight and tumor size were measured and calculated three times per week (29 (link)). The mice were sacrificed 4 weeks after the initiation of treatment. Tumor and organ tissues (liver, heart, lung, spleen, and kidney) were collected for H&E staining and immunostaining analyses.
Athymic nu nu
Manufactured by Taconic Biosciences
The Athymic nu/nu is a laboratory mouse model that lacks a functional thymus gland, resulting in a deficiency of T cells. This model is commonly used in research to study the effects of immune system dysfunction and to evaluate the efficacy of therapies targeting the immune system.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using athymic nu nu
1
Honokiol and Radiation Therapy for Nude Mouse Xenograft
2
In Vivo Tumor Growth Evaluation
3
Evaluating Anti-Tumor Efficacy of Cetuximab and MM-121 in Xenograft Model
4
Subcutaneous Xenograft Tumor Model
5
Combinational Therapy for Tumor Suppression
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The animal experiment was approved by the Institutional Animal Care and Use Committee of Emory University. KB-8-5 cells (5×105) were injected s.c. into 4–5 week-old female nude mice (Athymic nu/nu, Taconic NY). When the tumors had developed to about 100 mm3, the mice were divided into four groups (n = 7 or 8) in a way to minimize weight and tumor size differences among the groups: control group treated with 20% intralipid (Baxter Healthcare), honokiol group (1.0 mg/mouse or 50 mg/kg), paclitaxel group (20 mg/kg), and honokiol (1.0 mg/mouse or 50 mg/kg) plus paclitaxel (20 mg/kg) combination group. Honokiol was dissolved in 100% ethanol and mixed with 20% intralipid in a 1∶14 (v/v) ratio. Honokiol was administered to the mice 3 times per week at 1.0 mg/mouse (or 50 mg/kg) via intraperitoneal injection. Paclitaxel was administered to the mice once per week at 20 mg/kg through tail vein injection. The therapy was continued for 4 weeks. The body weight and tumor size were measured three times per week. The tumor volume was calculated using the formula: V = //6 × larger diameter × (smaller diameter) [13] (link). The mice were sacrificed 4 weeks after the initiation of treatment. Tumor and organ tissues (liver, heart, lung, spleen, and kidney) were collected for H&E staining and immunostaining analyses.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!